UA78516C2 - Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity - Google Patents

Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity Download PDF

Info

Publication number
UA78516C2
UA78516C2 UA2004031727A UA2004031727A UA78516C2 UA 78516 C2 UA78516 C2 UA 78516C2 UA 2004031727 A UA2004031727 A UA 2004031727A UA 2004031727 A UA2004031727 A UA 2004031727A UA 78516 C2 UA78516 C2 UA 78516C2
Authority
UA
Ukraine
Prior art keywords
cells
hypersensitivity
mice
inhibitor
type
Prior art date
Application number
UA2004031727A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of UA78516C2 publication Critical patent/UA78516C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
UA2004031727A 2001-08-10 2002-01-08 Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity UA78516C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118811 2001-08-10
EP02100735 2002-06-20
PCT/EP2002/008591 WO2003013577A2 (fr) 2001-08-10 2002-08-01 Utilisation d'inhibiteurs de il-18 pour le traitement de troubles d'hypersensibilite

Publications (1)

Publication Number Publication Date
UA78516C2 true UA78516C2 (en) 2007-04-10

Family

ID=26076673

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2004031727A UA78516C2 (en) 2001-08-10 2002-01-08 Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity

Country Status (26)

Country Link
US (1) US20040247598A1 (fr)
EP (1) EP1423138B1 (fr)
JP (1) JP4301942B2 (fr)
KR (1) KR20040030948A (fr)
CN (1) CN100500210C (fr)
AR (1) AR035274A1 (fr)
AU (1) AU2002331376B2 (fr)
BR (1) BRPI0211827B8 (fr)
CA (1) CA2456247C (fr)
CY (1) CY1116137T1 (fr)
DK (1) DK1423138T3 (fr)
EA (1) EA006745B1 (fr)
ES (1) ES2533253T3 (fr)
HR (1) HRP20040071B1 (fr)
HU (1) HU230377B1 (fr)
IL (2) IL160230A0 (fr)
ME (1) ME00547B (fr)
MX (1) MXPA04001230A (fr)
NO (1) NO335688B1 (fr)
PL (1) PL227130B1 (fr)
PT (1) PT1423138E (fr)
RS (1) RS52224B (fr)
SI (1) SI1423138T1 (fr)
UA (1) UA78516C2 (fr)
WO (1) WO2003013577A2 (fr)
ZA (1) ZA200400442B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177907B1 (fr) * 2004-06-30 2014-01-01 Atsuo Sekiyama Agent indicateur d'une réponse au stress non inflammatoire et son utilisation
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
CN103458904B (zh) * 2010-12-16 2016-09-28 株式会社明治 格氏乳杆菌的菌体级分在制造用于减轻迟发型变态反应的组合物中的用途
CN121586728A (zh) * 2023-06-20 2026-02-27 阿波罗Ap43有限公司 用于治疗特应性皮炎的抗il-18抗体疗法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
WO1999046248A1 (fr) * 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated DERIVES DE LA 1,2-DIAZEPANE INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
CA2276216A1 (fr) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide artificiel capable de neutraliser l'activite biologique de l'interleukine-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
WO2000071719A1 (fr) * 1999-05-20 2000-11-30 Hyseq, Inc. Substances liees a l'interleukine-1 hy2 (il-1 hy2) et procedes
WO2002032374A2 (fr) * 2000-10-18 2002-04-25 Immunex Corporation Methodes de traitement de troubles induits par l'il-18

Also Published As

Publication number Publication date
ZA200400442B (en) 2005-03-30
BRPI0211827B8 (pt) 2021-05-25
RS52224B (sr) 2012-10-31
BR0211827A (pt) 2004-08-31
YU11904A (sh) 2006-08-17
BRPI0211827B1 (pt) 2019-07-23
CA2456247C (fr) 2013-09-10
IL160230A (en) 2014-11-30
EP1423138B1 (fr) 2014-12-24
HRP20040071A2 (en) 2004-10-31
WO2003013577A3 (fr) 2003-09-25
CN1568193A (zh) 2005-01-19
NO20040370L (no) 2004-03-23
PL227130B1 (pl) 2017-10-31
AR035274A1 (es) 2004-05-05
US20040247598A1 (en) 2004-12-09
KR20040030948A (ko) 2004-04-09
HUP0401323A3 (en) 2006-01-30
MXPA04001230A (es) 2004-05-27
SI1423138T1 (sl) 2015-04-30
PT1423138E (pt) 2015-02-09
JP2005501080A (ja) 2005-01-13
PL368231A1 (en) 2005-03-21
EA006745B1 (ru) 2006-04-28
EA200400296A1 (ru) 2004-06-24
DK1423138T3 (en) 2015-02-23
CY1116137T1 (el) 2017-02-08
HU230377B1 (hu) 2016-03-29
HRP20040071B1 (hr) 2015-08-28
CN100500210C (zh) 2009-06-17
HK1069780A1 (zh) 2005-06-03
EP1423138A2 (fr) 2004-06-02
AU2002331376B2 (en) 2007-06-14
ES2533253T3 (es) 2015-04-08
NO335688B1 (no) 2015-01-19
IL160230A0 (en) 2004-07-25
WO2003013577A2 (fr) 2003-02-20
CA2456247A1 (fr) 2003-02-20
ME00547B (me) 2011-12-20
HUP0401323A2 (hu) 2004-10-28
JP4301942B2 (ja) 2009-07-22

Similar Documents

Publication Publication Date Title
JP5887441B2 (ja) Ｒａｇｅ融合タンパク質
EP2152287B1 (fr) Procédés de traitement et de prévention du syndrome gi et de la réaction de greffe contre l'hôte
US20200030377A1 (en) Antigen-specific immune modulation
WO2016167263A1 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
Kremsner et al. Interferon‐γ induced lethality in the late phase of Plasmodium vinckei malaria despite effective parasite clearance by chloroquine
DE69630682T2 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
UA78516C2 (en) Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
KR20080079702A (ko) 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도
CA2582471A1 (fr) Agents bloquants de l'interferon de type 1 dans la prevention et le traitement du psoriasis
Hurley et al. Eosinophilia and acquisition of resistance to Nematospiroides dubius in mice sensitized with adult worms
AU2002331376A1 (en) Use of IL-18 inhibitors in hypersensitivity disorders
KR101606645B1 (ko) 다우리놀 화합물을 유효성분으로 포함하는 면역질환의 예방 및 치료용 조성물
US20250161399A1 (en) Targeting slc46a2-mediated muropeptide transport to treat psoriasis
KR102959210B1 (ko) 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도
Rolland et al. Anti-lymphocyte serum: a review of its immunological effects and therapeutic value
Colagiovanni et al. TNF-α Blockade by a Dimeric TNF Type I Receptor Molecule Selectively Inhibits Adaptive Immune Responses
JP2008524114A (ja) ｉＮＯＳを産生する病気に対する改善された治療薬剤
Bozza et al. III-1 MIF in Infectious Diseases
Bass The Eosinophil leucocyte: a cell in search of a role
Moore et al. iuition. feeds, and feeding (second ulletin No. 1113, Mississippi State